Kane Biotech Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

OTCPK:KNBI.F Recent Insider Transactions by Companies or Individuals
Date	Value	Name	Entity	Shares	Max Price
17 Jan 25	BuyUS$138,832	Marc Edwards	Individual	2,000,000	US$0.069
17 Jan 25	BuyUS$69,416	Philip Renaud	Individual	1,000,000	US$0.069
17 Jan 25	BuyUS$6,942	Ray Dupuis	Individual	100,000	US$0.069
17 Jan 25	BuyUS$41,650	Robert Huizinga	Individual	600,000	US$0.069
01 Oct 24	BuyUS$22,408	Robert Huizinga	Individual	242,000	US$0.093
13 Sep 24	BuyUS$8,283	Robert Huizinga	Individual	90,000	US$0.092
11 Sep 24	BuyUS$183,815	Richard Renaud	Individual	2,500,000	US$0.074
29 Jul 24	BuyUS$14,616	Marc Edwards	Individual	150,000	US$0.097
25 Jun 24	BuyUS$35,369	Marc Edwards	Individual	345,000	US$0.10
17 Apr 24	SellUS$188,348	Philip Renaud	Individual	2,000,000	US$0.094

Insider Trading Volume

Insider Buying: KNBI.F insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

What is the ownership structure of KNBI.F?
Owner Type	Number of Shares	Ownership Percentage
Individual Insiders	54,070,590	35.9%
General Public	96,465,977	64.1%

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.

Top Shareholders

Top 6 shareholders own 35.92% of the company

Ownership	Name	Shares	Current Value	Change %	Portfolio %
17.5%	Philip Renaud	26,389,711	US$2.0m	3.94%	no data
11.4%	Richard Renaud	17,130,333	US$1.3m	17.1%	no data
5.57%	Marc Edwards	8,383,142	US$644.6k	31.3%	no data
0.72%	Ray Dupuis	1,085,404	US$83.5k	10.2%	no data
0.62%	Robert Huizinga	932,000	US$71.7k	936%	no data
0.1%	Georges Morin	150,000	US$11.5k	0%	no data

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/02/06 10:41
End of Day Share Price	2025/02/06 00:00
Earnings	2024/09/30
Annual Earnings	2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Kane Biotech Inc. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.